Clinical trials: Colorectal Cancer Recurrent
Colonic Neoplasms, Neoplasm Recurrence, Local
Incidence, Risk Factor, Treatment and Overall Survival of Locoregionally Recurrent Colon Cancer
Data on disease recurrence was collected for all primary colon cancer patients diagnosed in the Netherlands over the first six months of 2015.
- Trial name
- NCT05475288
- Volunteers
- 3,554 people
- Sponsor
- Radboud University Medical Center
Colorectal Cancer, Hereditary Non-polyposis Colon Cancer
Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer
RATIONALE: The use of a CD-ROM may help patients with colorectal cancer or a family history of colorectal cancer make informed decisions about undergoing microsatellite instability (MSI) testing.
- Trial name
- NCT00450424
- Testing
- counseling intervention, CD-ROM intervention
- Where
- 3 sites in United States
- Volunteers
- 239 people
- Sponsor
- Fox Chase Cancer Center
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
Colorectal Cancer
OSI-7904L and Oxaliplatin in Treating Patients With Refractory or Recurrent Advanced Colorectal Cancer
RATIONALE: OSI-7904L may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00081237
- Testing
- OSI-7904L, oxaliplatin
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 15 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Anal Intraepithelial Neoplasia, Anal Cancer
HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL
Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) worldwide. Infection by certain high-risk oncogenic types of HPV (HR-HPV) is the major cause of several cancers in men, notably squamous cell…
- Conditions
- Anal Intraepithelial Neoplasia, Anal Cancer, Human Papilloma Virus
- Trial name
- NCT03947775
- Testing
- 9-valent HPV vaccination
- Where
- 4 sites in Canada
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Breast Cancer, Colorectal Cancer
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Vaccines made from a person's white blood cells that have been treated in the laboratory may make the body build an immune response to kill tumor cells.
- Conditions
- Breast Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer
- Trial name
- NCT00027534
- Testing
- TRICOM-CEA(6D)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Michael Morse, MD
Colorectal Neoplasms
S0820, Adenoma and Second Primary Prevention Trial
The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0…
- Trial name
- PACES (NCT01349881)
- Testing
- Eflornithine plus sulindac
- Where
- 989 sites in United States
- Volunteers
- 354 people
- Sponsor
- SWOG Cancer Research Network
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004102
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- United States
- Sponsor
- NYU Langone Health
Non-colorectal Cancer, Pancreatic Cancer
Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors
RATIONALE: Monoclonal antibodies, such as maytansinoid DM4-conjugated humanized monoclonal antibody huC242, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00352131
- Testing
- HuC242-DM4
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- ImmunoGen, Inc.
Colorectal Cancer
SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic or locally recurrent colorectal cancer. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor.
- Trial name
- NCT00006001
- Testing
- semaxanib
- Where
- 10 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2
Phase II trial to study the effectiveness of the monoclonal antibody trastuzumab and chemotherapy with irinotecan in treating patients who have stage IV colorectal cancer that overexpresses HER2.
- Trial name
- NCT00003995
- Testing
- trastuzumab, irinotecan hydrochloride
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma
This is a prospective randomized phase II trial was done in clinical oncology department at Kasr Alainy hospital, Cairo university (NEMROCK) to evaluate the role of intensification of chemotherapy in the first line for treatment…
- Trial name
- NCT05316818
- Testing
- FOLFOXIRI Protocol
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Kasr El Aini Hospital
Extensive Stage Small Cell Lung Cancer, Recurrent Colon Cancer
Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer
This randomized phase I trial studies the side effects, best way to give, and best dose of docetaxel when given together with vaccine therapy and sargramostim in treating patients with metastatic lung cancer or metastatic…
- Conditions
- Extensive Stage Small Cell Lung Cancer, Recurrent Colon Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00088933
- Testing
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)-TRICOM vaccine, docetaxel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Metastatic, Colorectal Cancer Recurrent
Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer
The goal of this clinical trial is to demonstrate the non-inferiority of trifluridine/tipiracil + regorafenib vs trifluridine/tipiracil + bevacizumab in terms of progression free survival in patients with refractory metastatic…
- Trial name
- REGTAS-2 (NCT06992648)
- Testing
- Trifluridine/Tipiracil + Regorafenib, Trifluridine/tipiracil + bevacizumab
- Where
- China
- Volunteers
- 302 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Chemotherapeutic Agent Toxicity, Colorectal Cancer
Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan
RATIONALE: Calcium aluminosilicate anti-diarrheal (CASAD) may help treat and prevent diarrhea caused by irinotecan. It is not yet known whether CASAD is more effective than a placebo in treating and preventing diarrhea in…
- Conditions
- Chemotherapeutic Agent Toxicity, Colorectal Cancer, Diarrhea
- Trial name
- NCT00748215
- Testing
- calcium aluminosilicate anti-diarrheal
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer Pain, Visceral Pain
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL).
- Conditions
- Cancer Pain, Visceral Pain, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract
- Trial name
- NCT04907643
- Testing
- PICO G2 4k
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Cedars-Sinai Medical Center
Rectal Cancer Patients
Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）
To evaluate the safety and preliminary efficacy of preoperative chemotherapy and PD-1 inhibitor Tislelizumab for Rectal Cancer patients.Go through laboratory and medical tests to verify eligibility to enter the study, receive the…
- Trial name
- NCT06647680
- Testing
- Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles
- Where
- China
- Volunteers
- 35 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Gardner Syndrome, Colorectal Carcinoma
A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome
The purpose of this study is to assess the long-term outcome in a cohort of Gardner-Syndrome patients receiving prophylaxis and treatment for intestinal and non-intestinal tumors.
- Conditions
- Gardner Syndrome, Colorectal Carcinoma, Desmoid Tumor
- Trial name
- NCT01286662
- Volunteers
- 105 people
- Sponsor
- Triemli Hospital
Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors.
- Conditions
- Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Breast Cancer
- Trial name
- NCT00089362
- Testing
- alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Rehabilitation, Colorectal Cancer Survivor
Multidimensional Rehabilitation Intervention in Colorectal Cancer Survivors - a Pilot Study
A metaverse-based multidimensional rehabilitation program will be implemented for colorectal cancer survivors who have undergone curative surgery and adjuvant therapy.
- Conditions
- Rehabilitation, Colorectal Cancer Survivor, Quality of Life, Pilot Study
- Trial name
- NCT05957289
- Testing
- multidimensional rehabilitation
- Volunteers
- 10 people
- Sponsor
- Qu Shen